← All trials
NCT04087733
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2019
- Primary completion
- Nov 3, 2019
- Completion date
- Dec 31, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 200
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of MoliseLead sponsor
- University of GenoaCollaborator
- University of PaviaCollaborator
- University of BolognaCollaborator
- University of FlorenceCollaborator
- University of PisaCollaborator
- D'Annunzio University of Chieti–PescaraCollaborator
- A.O. Ospedale Maggiore di LodiCollaborator
- University of Roma La SapienzaCollaborator
- University of MoliseOverall official - principal investigator
- S.Eugenio HospitalCollaborator
- Ospedale Oftalmico, TorinoCollaborator
- OSPEDALE POLICLINICO G.B. ROSSICollaborator
- Clinica MediterraneaCollaborator
- Government of ItalyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.